Expression of biomolecular markers (Ki-67, PCNA, Bcl-2, BAX, BclX, VEGF) in breast tumors

Bulletin of Experimental Biology and Medicine

Volumn 137, Issue 2, 2004, Pages 182-185

  Kushlinskii, N E ^a   Orinovskii, M B ^a   Gurevich, L E ^a   Kazantseva, I A ^a   Talaeva, Sh Zh ^a   Shirokii, V P ^a   Ermilova, V D ^a   Dvorova, E K ^a   Ozherel'ev, A S ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Breast cancer; Ki 67, PCNA, Bcl 2, BAX, BclX, VEGF expression; Prediction

Indexed keywords

BIOCHEMICAL MARKER; CYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; TAMOXIFEN; VASCULOTROPIN; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MASTECTOMY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4344633245     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BEBM.0000028135.91289.e9     Document Type: Article

References (14)

1. E. S. Gershtein and N. E. Kushlinskii, Prakt. Onkol., 3, No. 1, 38-44 (2002).
2. N. E. Kushlinskii and E. S. Gershtein, Byull. Eksp. Biol. Med., 133, No. 6, 604-612 (2002).
3. N. N. Trapeznikov and E. M. Aksel', Malignant Tumors Morbidity and Mortality in the Population of the CIS Countries [in Russian], Moscow (2001).
4. J. Adams, P. J. Carder, S. Downey, et al., Cancer Res., 60, No. 11, 2898-2905 (2000).
5. K. Anan, T. Morisaki, M. Katano, et al., Eur. J. Surg. Oncol., 24, No. 1, 28-33 (1998).
6. S. W. Beenken and K. I. Bland, Minerva Chir., 57, No. 4, 437-448 (2002).
7. A. Biroccio, A. Candiloro, M. Mottolese, et al., FASEB J., 14, No. 5, 652-660 (2000).
8. N. Ferrara, Breast Cancer Res. Treat., 36, No. 2, 127-137 (1995).
9. J. Folkman, J. Natl. Cancer Inst., 82, 4-6 (1990).
10. G. Gasparini, Crit. Rev. Oncol. Hematol., 37, No. 2, 97-114 (2001).
11. T. Kato, S. Kameoka, T. Kimura, et al., Anticancer Res., 22, No. 2B, 1097-1103 (2002).
12. A. Kranz, T. Mattfeldt, and J. Waltenberger, Int. J. Cancer, 84, No. 3, 293-298 (1999).
13. M. Toi, S. Hoshina, T. Takayanagi, and T. Tominaga, Jpn. J. Cancer Res., 85, 1045-1049 (1994).
14. H. Trihia, S. Murray, K. Price, et al., Cancer, 97, No. 5, 1321-1331 (2003).